Introduction {#sec1-1}
============

Vitamin D (VD) is a fat-soluble vitamin and an endocrine hormone that plays a role in bone formation and integrity via calcium and phosphate absorption from the intestine and their transfer to bones. VD is also involved in proliferation and differentiation of different malignancies including prostate, breast, bone and leukemias. Effect of VD as hormone on metabolism and immunecell regulation of skin is also discussed. Studies have been reported immunomodulatory effect of VD and its analogues as skin protecting agents during exposure to UV.^[@ref1]^ Also, modification of vitamin D receptor (VDR) can be a clinical approach in multiple cancers like leukemias.^[@ref2]^ 25-hydroxyvitamin D3 (25(OH) D3) and 1alpha 25-hydroxyvitamin D3 (1α 25(OH)~2D3~) are the most abundant and most active forms of VD, respectively. A low level of 25(OH)~2~D3 is associated with a poor function of the immune system. Several genes appear to respond to 1α 25(OH)~2~D3,^[@ref3]^ and the fact that many genes are affected by VD further illustrates the importance of studying VD and its receptor polymorphisms. VD is involved in the process of cell proliferation, angiogenesis, and even metastasis through the regulation of gene expression.^[@ref4]^ High serum levels of VD in different malignancies, including breast, colorectal, and prostate cancers, are associated with the reduced incidence risk of these cancers.^[@ref5]^ It has also been shown that VD plays a positive role in preventing angiogenesis as well as metastasis and that it has the ability to modulate the innate and adaptive immune system, affecting the proliferation of T helper type 1 (Th1) lymphocytes by repressing immune factors such as interferon gamma (IFNγ). VD is also capable of controlling the differentiation of immune cells such as Dendritic Cells (DCs), which indicates its immunosuppressive role along with calcium (Ca) homeostasis in immune processes.^[@ref3]^

VDR is a polymorphic gene. rs1544410 (Bsm I), rs7975232 (Apa I), rs2228570 (Fok I), rs731236 (Taq I), and rs11568820 (Cdx2) are among the polymorphisms specifically addressed in this review. Essentially, these polymorphisms are enzymes that are distinguished due to the variances in their restriction enzyme cleavage sites.^[@ref11]^ VDR is a transcriptional factor (TF) binding 1α 25(OH)~2~D3 in extremely low concentrations, and the effects of VD hormone are thus mediated by VDR.^[@ref3]^ The relationship between VDR and the pathogenesis of prostate, breast, melanoma, and colorectal cancers has been reported.^[@ref5],12,[@ref13]^ In recent years, due to further attention to VDR, the prominent role of this TF in various signaling pathways, including mitogen-activated protein kinase (MAPK) and phosphatidylinositol-3-kinase/protein kinase B/mammalian target of rapamycin (PI3K/ATK/mTOR), has been demonstrated. The importance of this involvement is that the mentioned signaling pathways can lead to cellular differentiation during the signaling process in collaboration with VDR.^[@ref10]^ Extensive evidence suggests the regulatory role of VDR in various signaling pathways. VDR can regulate different components of several pathways, thereby influencing apoptosis, autophagy, cellular adhesion, and other processes effective upon the pathophysiology of leukemia/lymphoma.^[@ref3]^ It also affects the growth and proliferation of lymphocytes in the immune system by targeting immune mediators. ^[@ref14],[@ref15]^

The above-mentioned findings demonstrate the evident role of VD in immune and hematopoietic functions, which, as previously mentioned, are mostly mediated by VDR. In this review, we will discuss the likely role of VD level as a prognostic biomarker in leukemia, we will refer to the significant relationship between VDR polymorphisms and various types of leukemia, and for the first time we will thoroughly review the relationship between VD and VDR polymorphisms in leukemia.

Vitamin D and gene regulation {#sec1-2}
=============================

In general, the involvement of VDR in nine signaling pathways has been reported. Among the cellular signaling pathways associated with VDR, three pathways have been studied more extensively than others: Lipid Signaling Pathway, PI3K Pathway, and MAPK pathway, in which VD plays an important role.^[@ref4]^ Studies have identified a group of hematopoietic regulator networks, including a network with presence of VDR that is involved in the differentiation of granulocytes and monocytes. On the other hand, the involvement of 1α 25(OH)~2~D3 in monocyte differentiation has been indicated.^[@ref3]^ In a study using Iregulon plugin in Cytoscape software, 1045 target genes have been recognized for VDR.^[@ref16]^ Following the classification of these genes based on their biological roles, it was found that 68 genes were present in cancer-related pathways, and that 40 genes were among the markers dysregulated in various cancers. In addition, 54 genes were among the factors that played a role in MAPK signaling pathway ([Table 1](#table001){ref-type="table"}). This classification was based on the Kyoto encyclopedia of genes and genome (KEGG) database.^[@ref17]^ MAPK pathway has been recognized as one of the most important pathways involved in the development of cancers, especially leukemias.^[@ref18]^

Vitamin D level in leukemia/lymphoma {#sec1-3}
====================================

Most patients with newly diagnosed acute myeloblastic leukemia (AML) show VD deficiency, and low levels of VD are significantly associated with poor disease outcomes, but higher VD levels are related with a better outcome.^[@ref19]^ VD level seems to be related to translocation type; for example, most patients with internal tandem duplications of fms-like tyrosine kinase 3 (FLT3- ITD) are associated with low VD levels, and the improvement of VD serum levels can entail better outcomes in patients.^[@ref20]^

VD dicreases proliferation and increases differentiation of hematopoietic stem cell (HSC) via modulation of main regulatory pathways for HSC proliferation and survival such as MAPK pathway and PI3K/AKT/mTOR.^[@ref21]^ So hypothetically and based on this finding we can assume that VD and its analogues can inhibit excess proliferation of Leukemic stem cell (LSC) in leukemias. Also, it has been reported that co-treatment of leukemic cells with VD or its analogues modulate proliferation and differentiation of leukemic cells through changing the expression of hematopoietic growth factors, cytokines and their receptors.^[@ref22]^ In addition, studies suggested that the effect of VD and its analogues as a differentiation therapy on leukemic cells relied on different cytogenetic abnormalities of leukemic blast cells.^[@ref23]^ It is of note that combination of antioxidants and ceramide derivatives with VD or its analogues not only increased differentiation related cell cycle arrest of leukemic cells but also limited side effects of VD like hypercalcemia. Such differentiation agents in combination of VD can be an effective candidate for the treatment of leukemias.^[@ref24],[@ref25]^ It is interesting that hematopoietic differentiation control of VD derivatives is attributed to inhibition and induction of erythroid and monocytic differentiation, respectively.^[@ref26],[@ref27]^ It has been suggested that p27kip1, a cell cycle regulator of MAPK pathway, is a target gene of miR-181a and modulation of this miR can confer differentiation in cell lines such as HL60 and U937.^[@ref28]^ So, hypothetically modulation of miR-181a could be of therapeutic importance in AML. Evaluation of low VD levels and their effects on Azacitidine, which is a chemotherapy drug used in patients with secondary oligoblastic AML and myelodysplastic syndrome (MDS), showed that elevating VD levels following treatment with this drug could lead to increased survival of patients. The *in vitro* synergistic antiproliferative effect of Azacitidine in combination with VD has likely led to this improvement.^[@ref29]^ In children with acute lymphoblastic leukemia (ALL), it has also been shown that low levels of VD and the consequent defect in Ca homeostasis are directly related to clinical outcomes of ALL patients, including skeletomuscular pain.^[@ref12]^

In Chronic Lymphoblastic Leukemia/Small Lymphoblastic Lymphoma (CLL/SLL), inadequate levels of VD have been associated with decreasing time to treatment and undesirable overall survival (OS) in patients. Assessment of the efficacy and safety of VD supplementation indicated that VD levels could be corrected without any risk for patients by administering different VD doses as required.^[@ref30],[@ref31]^ The result of this study confirmed the prognostic role of VD levels in CLL/SLL since the VD levels have shown a significant correlation with OS. In Follicular Lymphoma (FL), there is a strong correlation between low VD levels and a poor outcome of FL.^[@ref32]^ The study of cutaneous T-cell lymphoma (CTCL) patients with Mycosis Fungoides and Sezary's Syndrome showed that the correction of VD deficiency and the type of supplement had no effect on overall clinical response, while vitamin deficiency affected the reduced synthesis of antimicrobial peptides mediated by VDR pathway, which was possibly associated with chronic infections in CTCL patients.^[@ref33]^ Among Non-Hodgkin's Lymphomas (NHL), Diffuse Large B-cell Lymphoma (DLBCL) patients having high interleukin 10 (IL-10) levels are associated with a poorer event-free survival (EFS) than those with lower IL- 10 levels.^[@ref34]^ IL-10 is a target of VDR,^[@ref35]^ and perhaps the use of VD and its analogues repress this cytokine through VDR mediation. Investigation of the relationship between VD deficiency with DLBCL and T-cell lymphoma revealed that VD deficiency was associated with inferior OS and EFS in both diseases.^[@ref36]^ In DLBCL patients treated with Rituximab, VD deficiency has been introduced as a risk factor, because VD deficiency inhibits the Rituximab-mediated toxicity; therefore, VD correction could increase the efficacy of Rituximab.^[@ref37]^ There are also reports of the prognostic role of VD in other hematologic malignancies; for example, VD deficiency is an undesirable prognostic marker in multiple myeloma (MM).^[@ref38],[@ref39]^ Thus, considering these findings, we can hypothesize that not only the prevalence of VD deficiency is high in hematologic malignancies, but it reduces the response of these patients to treatment. It is recommended to conduct clinical trials to evaluate the effect of VD supplementation on the therapeutic outcomes of these patients. Increasing Ca concentrations in CLL patients is associated with increased survival and proliferation of B-cells, as well as their resistance to apoptosis.^[@ref40]^

Role of vitamin D receptor polymorphisms in leukemias {#sec1-4}
=====================================================

Acute leukemias {#sec2-1}
---------------

Apa I, Fok I, Taq I, and Bsm I are important polymorphisms of VDR gene, which have been closely correlated with AML. For example, Taq I expression is associated with Complete Remission (CR) and prognosis, so that 70% of CR patients have the TC genotype and 30% have TT genotype of Taq I polymorphism.^[@ref41]^ In the study of children with ALL, Apa I, Taq I, Bsm I, Cxd2, and GATA polymorphisms have been evaluated. In ALL patients, Bone Mineral Density (BMD) is damaged due to corticosteroid and methotrexate (MTX) consumption. Since the Tt genotype of Taq I and Bb genotype of Bsm I are related with a higher BMD in ALL patients, it is likely that the patients harboring these polymorphisms show a better response to treatment and be more resistant to drug-induced damage^[@ref42]^ ([Table 2](#table002){ref-type="table"}).

Chronic leukemias {#sec2-2}
-----------------

The analysis of Fok I polymorphism in Chronic Myeloblastic Leukemia (CML) patients showed that ff was the dominant genotype among patients.^[@ref43]^ This allele has already been shown to be associated with an increased risk of T-cell lymphoma.^[@ref44]^ According to these findings, it may be assumed that the f allele has an uncertain role in the pathogenesis of CML, and further research is needed to understand its role and effect on prognosis of the disease, while this allele might also be used as a prognostic factor because its presence is related with a higher risk of T-cell lymphoma.

The antagonistic effect of microRNA-214 (miR-214) on VDR signaling and inhibiting Hedgehog (Hh) signaling has been reported. ^[@ref45]^ Studies have shown that Hh antagonists may play a role in the treatment of CML and B-ALL.^[@ref46],[@ref47]^ VDR antagonists inhibiting Hh signaling are likely to treat patients with CML and even patients with other leukemia types. There is a relationship between the mutated Ff genotype of Fok I polymorphism and the increased risk of CLL, but this relationship has little effect on the clinical outcome of the disease^[@ref48]^ ([Table 3](#table003){ref-type="table"}).

Lymphomas {#sec2-3}
---------

Fok I polymorphism in Plasmablastic Lymphoma (PBL) potentiates tumor growth inhibition.^[@ref49]^ A relationship has been reported between Taq I, Fok I, and Bsm I variants with some types of NHL; for example, the B allele of Bsm I polymorphism and t allele of Taq I polymorphism are associated with DLBCL, and the f allele of Fok I polymorphism is related with T-cell lymphoma.^[@ref44]^ The study of Hodgkin's lymphoma (HL) and NHL cases showed that VDR was strongly expressed on HL tumor cells, and it was concluded that VDR was a diagnostic factor for HL. However, as there was not a high expression of VDR in NHL cases, the same function of VDR in NHL was not addressed by this study.^[@ref50]^ In another study, no correlation was found between Fok I, Bsm I, Taq I, Apa I, and Cxd2 variants with disease progression in HL patients.^[@ref51]^ Increased interleukin-6 (IL-6) is a major cause of anemia in HL,^[@ref52]^ and because IL-6 gene is a target of VDR, it is possible to manipulate VDR and affect the expression of IL-6 gene to reduce anemia complications in HL patients. [Figure 1](#fig001){ref-type="fig"} shows vitamin D metabolism and targets of vitamin D receptor.

Other blood disorder {#sec1-5}
====================

In MM, the TT genotype of Taq I and the mutated C allele of Taq I have a significant relationship with increased risk of disease. ^[@ref53]^ Another study reported that Fok I polymorphism inhibited tumor growth in MM patients.^[@ref49]^ A study has indicated that DCs in MM patients have anabnormal function and that their defects are related to tumorigenicity in cancer. This study showed that enhanced IL-6 production by tumor, which was correlated with DC deficiency, led to the inhibition of precursor DC colonies and switched commitment of these CD34^+^ cells to monocytes.^[@ref54]^ On the other hand, studies have shown that IL-6 is among VDR targets repressing this cytokine.^[@ref15]^ Therefore, manipulation of VDR may reduce tumorigenesis of cancer by affecting IL-6.

In Aplastic Anemia (AA), GG genotype and G allele of Bsm I polymorphism are correlated with the increased risk of AA. Moreover, the supportive role of GA genotype and G allele of Bsm I has been raised in this disease. Carriers of TT genotype from Taq I polymorphism show a poor response to treatment and even have a higher risk of MDS/AML transformation,^[@ref55]^ and Taq I polymorphism could be considered as a prognostic biomarker for AA. Decreased expression of VDR may be related with hyperimmunity of AA patients, and VD supplementation may be able to partially correct the abnormal immune function of patients through the effects of VDR signaling pathway ([Table 4](#table004){ref-type="table"}).^[@ref56]^

Discussion {#sec1-6}
==========

Several genes are affected by VD and its receptor (VDR), through which VD regulates gene expression in vital biological processes and metastasis; on the other hand, VDR plays a role in cell differentiation via signaling pathways such as MAPK and PI3K^[@ref3],[@ref4],[@ref10]^ ([Table 5](#table005){ref-type="table"}). In this regard, anticancer activity of VDR is attributed to its inhibitory and promotion effect on proliferation and differentiation of malignant cells, respectively. Increased expression of p21 and p27 and consequently G0/G1 cell-cycle arrest is involved in differentiation process which is induced by VDR. So, VD, VDR and its analogues as differentiative inducer agents can be a therapeutical approach for leukemias in future.^[@ref57]^ The above findings justify the role and effect of VD and VDR in leukemia/lymphoma. A higher level of VD in serum of AML patients is associated with a good response to treatment, longer survival, and better prognosis; therefore, low VD levels can be considered as a risk factor that can be readily and economically improved.^[@ref19],[@ref20],[@ref29]^ Overall, low VD levels can be regarded as a biomarker of poor prognosis in patients with AML and ALL, which is associated with an unfavorable OS in patients with SLL/CLL and T-cell lymphoma.^[@ref12],[@ref19],[@ref30],[@ref31],[@ref36]^ Low VD is also indicative of a poor prognosis in MM.^[@ref38],[@ref39]^ Taq I seems to be a biomarker of good prognosis in ALL and AML, and mutated Fok I phenotypes due to the presence of f allele could be used as a prognostic marker in CML and CLL patients.^[@ref41],[@ref48]^ This is while Fok I in MM and PBL may be associated with a good prognosis.^[@ref49]^ Taq I polymorphism in MM is associated with an increased risk of associated disease and has prognostic value.^[@ref53]^ In AA, Bsm I and Taq I are associated with a poor prognosis.^[@ref55]^

The association between different miRs and VD and VDR should be studied more because of possible therapeutic role of miRs. It has been suggested that the active form of VD exerts its anti-tumor effects by regulation of gene transcription and miR regulation. ^[@ref58]^ MiR-214 is an antagonist of VDR. Studies indicate that miR-214 negatively regulates phosphatase and tensin homolog (PTEN) at protein level and activates the Akt signaling pathway, and that the reduced PTEN gene expression is related with a poor prognosis in AML. In patients with relapse, PTEN gene expression is lower than that of normal people. The role of miR-214 in the down regulation of PTEN gene has also been indicated in CLL.^[@ref45],[@ref59]^ Thus, considering the fact that miR-214 is an antagonist of VDR, miR-214 manipulation could resolve the negative effect of this miR on VDR, improving the prognosis of AML and CLL patients by increasing the expression of PTEN gene. Furthermore, VDR can play an important role in future therapeutic strategies of cancer via targeting a number of targets, particularly IL-2, IL-6, IL-10 cytokines as well as CDKN1B gene.^[@ref14],[@ref15],35,[@ref62]^ For instance, the aberrant IL-6 signaling contributes to cancer through signal transducer and activator of transcription 3 (STAT3). IL-2 and IL-6, which are among VDR targets, play a role in B-cell development. Therefore, the repression of these two cytokines by VDR following the consumption of VD and its analogues could have beneficial effects on CLL patients.^[@ref14],[@ref15]^

Conclusion and future perspectives {#sec1-7}
==================================

In summary, it was shown in this review that VD and VDR polymorphisms could be used as prognostic biomarkers for various types of leukemia/lymphoma, including AML, CLL/SLL, DLBCL, T-cell lymphoma, MM and AA. There is a significant relationship between polymorphisms of Taq I, Fok I, and Bsm I with leukemia/lymphoma.
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![Vitamin D metabolism and targets of vitamin D receptor are shown in this figure. Vitamin D receptor targets different genes and thus affects biological functions. VD: vitamin D; CYP: cytochrome P; DHCR-7: 7-Dehydrocholesterol reductase; VDR: vitamin D receptor; TSPAN7: Tetraspanin-7; BCL6: B-cell lymphoma 6 protein; LDB1: LIM domain-binding protein 1; MAX: myc-associated factor X; CEBPB: CCAAT/enhancer-binding protein beta; NR4A3: nuclear receptor subfamily 4, group A, member 3; RXRB: Retinoid X receptor beta; TCF3: Transcription factor 3; CDKN1B: Cyclin-dependent kinase inhibitor 1B; MMP9: Matrix metallopeptidase 9; ERG: *ETS-related gene*; *WT1*: Wilm\'s tumor; IGF1: Insulin-like growth factor 1; MLL: myeloid/lymphoid or mixed-lineage leukemia; RARA; Retinoic acid receptor alpha;FLI1: Friend leukemia integration 1; MDM2: Mouse double minute 2 homolog; IL2RB: Interleukin-2 receptor subunit beta; TRAF2: TNF receptor-associated factor 2; RAC2: Ras-related C3 botulinum toxin substrate 2; PDGFR: platelet-derived growth factor receptor; ATF2: Activating transcription factor 2; TGFB: Transforming growth factor beta; PTPN7: Protein tyrosine phosphatase non-receptor type 7; AKT1: RAC-alpha serine/threonine-protein kinase; FGFR1: Fibroblast growth factor receptor 1 ; FGF10; Fibroblast growth factor 10; MAPK10: Mitogen-activated protein kinase 10; PRKCG: Protein kinase C gamma type.](onco-12-2-366-g001){#fig001}

###### 

Evaluation of VDR targets by Iregulon plugin and cytoscape software.

  ID category   Category name                               Benjamini   P-value    Fold enrichment   N. Genes
  ------------- ------------------------------------------- ----------- ---------- ----------------- ----------
  hsa05200      Pathways in cancer                          2.53E-12    2.57E-15   2.762             68
  hsa04020      Calcium signaling pathway                   2.22e-11    4.50e-14   3.4               46
  hsa04360      Axon guidance                               1.61e-8     5.14e-11   3.484             34
  hsa04971      Gastric acid secretion                      1.61e-8     6.55e-11   4.45              25
  hsa04010      MAPK signaling pathway                      2.76e-8     1.40e-10   2.502             54
  hsa04725      Cholinergic synapse                         5.79e-8     4.11e-10   3.56              30
  hsa05202      Transcriptional dysregulation in cancer     5.79e-8     4.02e-10   2.909             40
  hsa04960      Aldosterone-regulated sodium reabsorption   1.59e-7     1.29e-9    5.609             17
  hsa04510      Focal adhesion                              2.66e-7     2.43e-9    2.667             42
  hsa05146      Amoebiasis                                  1.92e-6     1.95e-8    3.21              28

###### 

Different genotypes of Taq I polymorphism in acute leukemias.

  Effect of genotype                           Chromosome   Leukemia   Ref.
  -------------------------------------------- ------------ ---------- ------
  Tt genotype is associated with higher BMD    12q13.11     ALL        42
  TC and TT genotypes are associated with CR   12q13.11     AML        41

ALL: acute lymphoblastic leukemia; AML: acute myeloblastic leukemia; BMD: Bone mineral density; CR: Complete remission.

###### 

Different genotypes of Fok I polymorphism in chronic leukemias.

  Effect of genotype                                   Chromosome   Leukemia   Ref.
  ---------------------------------------------------- ------------ ---------- ------
  Ff genotype is associated with higher risk for CLL   12q13.11     CLL        48
  Ff genotype has a significant correlation with CML   12q13.11     CML        43

CLL: chronic lymphoblastic leukemia; CML: chronic myeloblastic leukemia.

###### 

VDR Polymorphisms related with leukemias.

  VDR gene polymorphism   Allele-genotypes   Chr.       Effection mechanism in prognosis                              Leukemia          Ref.
  ----------------------- ------------------ ---------- ------------------------------------------------------------- ----------------- ------
  Taq I                   TT and TC          12q13.11   CR and GP                                                     AML               41
  Taq I                   Tt                 12q13.11   Higher BMD                                                    ALL               42
  Bsm I                   Bb                 12q13.11   Higher BMD                                                                       
  Fok I                   F                  12q13.11   Probable role in CML pathogenesis                             CML               43
  Fok I                   Ff                 12q13.11   Higher risk for CLL                                           CLL               48
  \-                      \-                 \-         Strong expression of VDR may be a marker for HL tumor cells   HL                50
  Taq I                   T                  12q13.11   Correlated with DLBCL                                         DLBCL             44
  Fok I                   F                  12q13.11   Correlated with T cell lymphoma                               T cell lymphoma   44
  Taq I                   TT and C           12q13.11   Correlated with MM                                            MM                53
  Bsm I                   GG                 12q13.11   Higher risk for AA                                            AA                55
  Taq I                   TT                 12q13.11   Poor response to treatment                                                      

ALL: acute lymphoblastic leukemia; AML: acute myeloblastic leukemia; CLL: chronic lymphoblastic leukemia; CML: chronic myeloblastic leukemia; CR: Complete Remission; GP: Good Prognosis; BMD: Bone Mineral Density; HL: Hodgkin Lymphoma; DLBCL: Diffuse Large B Cell Lymphoma; MM: Multiple Myeloma; AA: Aplastic Anemia.

###### 

VDR targets in leukemias.

  Target gene   Chro.     Type of effect   Leukemia   Ref.
  ------------- --------- ---------------- ---------- ------
  CAMP          3p21.31   Unknown          AML        65
  CDKN1B        12p13.1   Activation       AML        62
  CYP1A1        15q24.1   Unknown          AML        64
  EGFR          7p11.2    Repression       AML        64
  HOXA10        7p15.2    Activation       AML        67
  IL-6          7p15.3    Repression       AML        15
  SKP2          5p13.2    Repression       AML        68
  CDKN1B        12p13.1   Unknown          ALL        63
  IL-10         1q32.1    Repression       ALL        35
  CDKN1B        12p13.1   Unknown          CML        63
  CYP1A1        15q24.1   Unknown          CML        64
  HOXA10        7p15.2    Activation       CML        67
  IL-2          4q27      Repression       CLL        14
  IL-6          7p15.3    Repression       CLL        15
  BGLAP         1q22      Unknown          MM         69
  CKN1B         12p13.1   Activation       MM         62
  IL-6          7p15.3    Repression       MM         15
  SKP2          5p13.2    Repression       MM         68
  CDKN1B        12p13.1   Activation       HL         63
  ERBB2         17q12     Unknown          HL         70
  IL-10         1q32.1    Repression       HL         35

CAMP: cathelicidin antimicrobial peptide; CDKN1B: cyclin dependent kinase inhibitor 1B; CYP1A1: cytochrome P450 family 1 subfamily A member 1; EGFR: Epidermal growth factor receptor; HOXA10: homeobox A10; IL-6: interleukin-6; SKP2: S-phase kinase associated protein 2; IL-10: interleukin-10; IL-2: interleukin-2; BGLAP: bone gamma-carboxyglutamate protein; ERBB2: erb-b2 receptor tyrosine kinase 2.
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